article thumbnail

FIP highlights hospital pharmacists’ unique role to support medicines access via rational drug use

Hospital Pharmacy Europe

The crucial role of hospital pharmacists in addressing challenges and improving access to safe, quality medicines and medical devices has been highlighted in a new reference document from the International Pharmaceutical Federation (FIP). This document highlights the importance of access to essential medicines.

article thumbnail

FDA’s Proposal to Remove Oral Phenylephrine from the OTC Monograph Isn’t a Surprise but What is Left “Over-the-Counter”?

The FDA Law Blog

Along with the proposed order, FDA issued as a supporting document the “ Scientific Review Supporting Proposed Administrative Order ” in which it describes the scientific data on the efficacy, pharmacology, and safety of oral PE underlying its determination to issue the proposed order. a); OTC Monograph M012: § M012.20.

FDA 109
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

UK biotech ‘booming’ as sector rakes in £1.6bn in Q2 financing

pharmaphorum

The new figures – from the BioIndustry Association and Clarivate – were dominated by more than £1 billion in venture capital funding for UK biotech and life sciences companies, headlined by DNA sequencing company Oxford Nanopore’s £195 million raise in May that was just shy of the £205 million record set by Immunocore in 2005.

article thumbnail

Annex 1 Implementation Strategies

ISPE

First published in 1989, there have been a total of 5 adaptations in 1996, 2003, 2005, 2007 and 2009, but no complete revision. Annex 1 of the EC GMP Guide " Manufacture of Sterile Medicinal Products " has a long history. In 2012, there was a proposal for a complete revision which resulted in a concept paper in 2015.

article thumbnail

The Ripple Effect: How Pharmaceutical Advertisements Impact the Industry and Beyond

Pharma Marketing Network

Narrative review: the promotion of gabapentin: an analysis of internal industry documents. Knopf Doubleday Publishing Group. Goozner, M. The $800 Million Pill: The Truth Behind the Cost of New Drugs. University of California Press. Steinman, M. Landefeld, C. S., & Bero, L. Annals of Internal Medicine, 155(1), 43-53.

article thumbnail

The Good, Bad, and Ugly side of 510(k)s—HP&M’s Early Experience with the eSTAR Template for 510(k)s

The FDA Law Blog

Lenz, Principal Medical Device Regulation Expert — Since 2005, 510(k) submissions have been formatted according to FDA guidance Format for Traditional and Abbreviated 510(k)s. Several sections of the eSTAR templates have questions that walk through related guidance documents. By Adrienne R. Know Your Guidances.

article thumbnail

EU fines Teva and Cephalon €60.5m for ‘pay for delay’ scheme

pharmaphorum

Although Teva and Cephalon are now the same company, the case dates back to June 2005 when the firms were separate entities. The deal was agreed well before Teva bought Cephalon in 2011 for $6.8 billion and involved a complex series of transactions instead of an up-front payment.